RhumbLine Advisers’s Edgewise Therapeutics EWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.47M | Buy |
112,483
+3,646
| +3% | +$47.8K | ﹤0.01% | 2052 |
|
|
2025
Q1 | $2.39M | Buy |
108,837
+6,440
| +6% | +$142K | ﹤0.01% | 1725 |
|
|
2024
Q4 | $2.73M | Buy |
102,397
+1,525
| +2% | +$40.7K | ﹤0.01% | 1724 |
|
|
2024
Q3 | $2.69M | Buy |
100,872
+2,603
| +3% | +$69.5K | ﹤0.01% | 1734 |
|
|
2024
Q2 | $1.77M | Buy |
98,269
+14,041
| +17% | +$253K | ﹤0.01% | 1949 |
|
|
2024
Q1 | $1.54M | Buy |
84,228
+19,895
| +31% | +$363K | ﹤0.01% | 2037 |
|
|
2023
Q4 | $704K | Buy |
64,333
+723
| +1% | +$7.91K | ﹤0.01% | 2473 |
|
|
2023
Q3 | $364K | Buy |
63,610
+330
| +0.5% | +$1.89K | ﹤0.01% | 2817 |
|
|
2023
Q2 | $490K | Buy |
63,280
+4,949
| +8% | +$38.4K | ﹤0.01% | 2699 |
|
|
2023
Q1 | $389K | Buy |
58,331
+7,341
| +14% | +$49K | ﹤0.01% | 2526 |
|
|
2022
Q4 | $456K | Buy |
50,990
+6,845
| +16% | +$61.2K | ﹤0.01% | 2507 |
|
|
2022
Q3 | $434K | Buy |
44,145
+2,431
| +6% | +$23.9K | ﹤0.01% | 2559 |
|
|
2022
Q2 | $332K | Buy |
41,714
+4,853
| +13% | +$38.6K | ﹤0.01% | 2708 |
|
|
2022
Q1 | $358K | Buy |
36,861
+6,350
| +21% | +$61.7K | ﹤0.01% | 2577 |
|
|
2021
Q4 | $466K | Buy |
+30,511
| New | +$466K | ﹤0.01% | 2537 |
|